API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
Through the agreement, LifeSci will present 7-MX (7-methylxanthine), a first-in-class oral therapy for the treatment and management of Myopia progression in children, to potential partners.
Lead Product(s): 7-Methylxanthine
Therapeutic Area: Ophthalmology Product Name: 7-MX
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: LifeSci Consulting
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement April 03, 2023